Donna L Senger

List of Publications by Year
in descending order

38 papers	2,381 citations	218677 26 h-index	345221 36 g-index
38 all docs	38 docs citations	38 times ranked	3370 citing authors

#	Article	IF	Citations
1	Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens. Stem Cells, 2009, 27, 1722-1733.	3.2	175
2	Rapid Retrograde Tyrosine Phosphorylation of trkA and Other Proteins in Rat Sympathetic Neurons in Compartmented Cultures. Journal of Cell Biology, 1997, 138, 411-421.	5.2	153
3	The p75 Neurotrophin Receptor Is a Central Regulator of Glioma Invasion. PLoS Biology, 2007, 5, e212.	5.6	150
4	Myxoma Virus Is a Novel Oncolytic Virus with Significant Antitumor Activity against Experimental Human Gliomas. Cancer Research, 2005, 65, 9982-9990.	0.9	149
5	Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide. Clinical Cancer Research, 2009, 15, 2777-2788.	7.0	142
6	Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. Clinical Cancer Research, 2016, 22, 3860-3875.	7.0	142
7	Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. Nature Communications, 2020, 11, 4997.	12.8	109
8	Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. Nature Communications, 2017, 8, .	12.8	103
9	Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin. Cancer Research, 2007, 67, 8818-8827.	0.9	97
10	Myxoma Virus Virotherapy for Glioma in Immunocompetent Animal Models: Optimizing Administration Routes and Synergy with Rapamycin. Cancer Research, 2010, 70, 598-608.	0.9	90
11	Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV Î”M51) on Multifocal and Invasive Gliomas. Journal of the National Cancer Institute, 2006, 98, 1546-1557.	6.3	88
12	Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma. Molecular Therapy, 2010, 18, 1927-1936.	8.2	83
13	Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver. Cell, 2019, 178, 1205-1221.e17.	28.9	80
14	Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals. Clinical Cancer Research, 2004, 10, 8561-8576.	7.0	78
15	Proteolytic Disassembly Is a Critical Determinant for Reovirus Oncolysis. Molecular Therapy, 2007, 15, 1512-1521.	8.2	76
16	Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury. Journal of Clinical Investigation, 2018, 128, 2894-2913.	8.2	74
17	Gamma-Secretase Represents a Therapeutic Target for the Treatment of Invasive Glioma Mediated by the p75 Neurotrophin Receptor. PLoS Biology, 2008, 6, e289.	5.6	66
18	Activation of NOTCH Signaling by Tenascin-C Promotes Growth of Human Brain Tumor-Initiating Cells. Cancer Research, 2017, 77, 3231-3243.	0.9	61

#	Article	IF	Citations
19	Novel <i>MSH6</i> Mutations in Treatment-NaÃ¯ve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of <i>MGMT</i> Promoter Methylation. Clinical Cancer Research, 2014, 20, 4894-4903.	7.0	51
20	Evidence that Protein Kinase C Activities Involved in Regulating Neurite Growth Are Localized to Distal Neurites. Journal of Neurochemistry, 1994, 63, 868-878.	3.9	47
21	Oncolytic Efficacy of Recombinant Vesicular Stomatitis Virus and Myxoma Virus in Experimental Models of Rhabdoid Tumors. Clinical Cancer Research, 2008, 14, 1218-1227.	7.0	47
22	Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro-Oncology, 2013, 15, 904-920.	1.2	44
23	Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19098-19108.	7.1	42
24	Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. Oncotarget, 2016, 7, 59360-59376.	1.8	34
25	Spatial requirements for TrkA kinase activity in the support of neuronal survival and axon growth in rat sympathetic neurons. Neuropharmacology, 2003, 45, 995-1010.	4.1	33
26	Spatial Regulation of Neuronal Gene Expression in Response to Nerve Growth Factor. Developmental Biology, 1997, 184, 1-9.	2.0	31
27	ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. PLoS ONE, 2018, 13, e0202860.	2.5	28
28	Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Research, 2019, 79, 2111-2123.	0.9	28
29	Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury. Science Advances, 2022, 8, eabm0142.	10.3	28
30	A Small Molecule Targeting the Transmembrane Domain of Death Receptor p75NTR Induces Melanoma Cell Death and Reduces Tumor Growth. Cell Chemical Biology, 2018, 25, 1485-1494.e5.	5.2	20
31	Development of a peptide-based delivery platform for targeting malignant brain tumors. Biomaterials, 2020, 252, 120105.	11.4	15
32	QuantitativeT2: interactive quantitative T2 MRI witnessed in mouse glioblastoma. Journal of Medical Imaging, 2015, 2, 1.	1.5	8
33	Eukaryotic initiation factor 5B (eIF5B) regulates temozolomide-mediated apoptosis in brain tumour stem cells (BTSCs). Biochemistry and Cell Biology, 2020, 98, 647-652.	2.0	4
34	N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells. Molecular Therapy - Oncolytics, 2016, 3, 16005.	4.4	2
35	To promote or inhibit glioma progression, that is the question for IL-33. Cell Stress, 2021, 5, 19-22.	3.2	2
36	Assessing Mechanisms of Glioblastoma Invasion. Neuromethods, 2012, , 275-298.	0.3	1

#	Article	IF	Citations
37	MTR-08MODELING TMZ RESISTANCE IN PATIENT-DERIVED BRAIN TUMOR- INITIATING CELLS. Neuro-Oncology, 2015, 17, v125.4-v126.	1.2	0
38	Overcoming therapeutic resistance in glioblastoma: Moving beyond the sole targeting of the glioma cells. , 2021, , 91-118.		0